ING Group’s Synergy Pharmaceuticals, Inc Common Stock SGYP Stock Holding History

ING Group’s Portfolio SGYP Stock Details SGYP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-17,500	Closed	-$32K	–	884
2018 Q1	$32K	Hold	17,500	–	–	﹤0.01%	715
2017 Q4	$39K	Hold	17,500	–	–	﹤0.01%	742
2017 Q3	$51K	Buy	+17,500	New	+$59.7K	﹤0.01%	812

Other funds holding SGYP

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Hikari Power Tokyo, Japan $855M AUM 14.24% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

KCM

Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return

ING Group's SGYP Position: Q2 2018 in Review

ING Group sold out of Synergy Pharmaceuticals, Inc Common Stock (SGYP) in Q2 2018, closing a stake of 17,500 shares — an estimated $32K sold.

ING Group first reported a position in SGYP in Q3 2017 and held it in 3 quarters. The position peaked at $51K in Q3 2017. 136 funds tracked by Wall St. Rank hold SGYP as of Q2 2018.

ING Group reported no remaining Synergy Pharmaceuticals, Inc Common Stock position as of Q2 2018 after selling out during the quarter.
ING Group sold 17,500 Synergy Pharmaceuticals, Inc Common Stock shares in Q2 2018, an estimated $32K.
ING Group first reported a position in Synergy Pharmaceuticals, Inc Common Stock in Q3 2017 and held it in 3 quarters.
ING Group's Synergy Pharmaceuticals, Inc Common Stock position peaked at $51K in Q3 2017.
136 funds tracked by Wall St. Rank held Synergy Pharmaceuticals, Inc Common Stock as of Q2 2018.

Based on ING Group's 13F filing for Q2 2018, filed 10 Aug 2018.